The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
[EN] FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] COMPOSÉS DIMÈRES AGONISTES DU RÉCEPTEUR FGF (FGFR), LEUR PROCÉDÉ DE PRÉPARATION ET LEUR USAGE THÉRAPEUTIQUE
申请人:SANOFI SA
公开号:WO2013098763A1
公开(公告)日:2013-07-04
The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M -L-M 2 in which M and M 2, which may be identical or different, each represent, independently of one another, a monomer unit Mand L represents a linker group which links M1 and M2 covalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof.
A new class of small molecules, with an unprecedented trifluorothiazoline scaffold, were synthesized and their pro‐apoptotic activity was evaluated. With an EC50 in the low micromolar range, these compounds proved to be potent inducers of apoptosis in a broad spectrum of tumor cell lines, regardless of the functional status of p53. Fast structure–activity relationship studies allowed the preparation